

14th Annual International **AASD** Conference

Arabic Association for the Study of
Diabetes and Metabolism (**AASD**)

Member of International Diabetes Federation, IDF

23-26 October 2018

Grand Nile Tower Hotel, Cairo, Egypt

23-25 October 2018

Workshop, IDF Centre of Education



14th AASD 2018

AASD & Conference Honorary President
Prof Raafat Rashwan

IDF President
Prof Nam Han Cho

AASD & Conference President
Prof Inass Shaltout

Conference Vice-President
Prof Omar El- Saadany


Conference & AASD General Secretary
Prof Abdel Khalek Hamed
Prof Mohamed Hassanein




AASD & Conference Honorary President
Prof Raafat Rashwan



IDF President
Prof Nam Han Cho



AASD & Conference President
Prof Inass Shaltout



Conference Vice-President
Prof Omar El-Saadany



Conference & AASD General Secretary
Prof Abdel Khalek Hamed **Prof Mohamed Hassanein**






Scientific Committee Chairmen

Prof Amr Abdel Wahab



Prof Ashraf Attia



Prof Atef Elbahry



Dr Nader Wadie



Scientific Committee Moderators

Prof Hala Kahla



Dr Ayman El Menofy



AASD Treasurer

Dr Sayed Gad



Organizing Committee Chairmen

Dr Mohamed Naguib



Dr Mazin Attia



Dr Hesham Habib



Organizing Committee Moderator

Dr Ahmed El Sabawy





**14th International Conference of
Arabic Association for the Study of Diabetes & Metabolism (AASD)
Member of International Diabetes Federation, IDF**

Dear professors and colleagues,

It gives us a great pleasure to welcome you in 14th annual AASD conference.

On behalf of AASD board and members, we appreciate the strong participation and support of International Diabetes Federation, IDF. AASD as a member of IDF puts a great responsibility on all AASD members to do extra efforts for the cause of Diabetes.

We appreciate the presence of our eminent guest speakers from United Kingdom, Italy, Spain, South Korea, Russia, Poland, Hungry, Macedonia, UAE, KSA, Morocco, Sudan and Bahrain for their presence to share in this outstanding scientific event. Their participation added a great scientific value to the conference.

On behalf of my colleagues, board and members of AASD, let me express my gratitude to all Egyptian professors & speakers who agreed to join us and Co-chair the Advisory board and National Faculty in this huge scientific event.

AASD as one of the leading Diabetes Associations has been recognized in December 2017 as an IDF center of education aims to share in:

1. Public awareness and patient education with the aim of prevention and optimum management.
2. Medical conferences intending to share knowledge and stimulate research.
3. Post graduate continuous medical education (AASD-CME).
4. Newsletters for health care professionals that intend to increase knowledge about the standards of medical care in diabetes and associated co-morbidities and complications.
5. Building the capacity of thousands of doctors, nurses and educating Patients which enhanced their knowledge to cope with diabetes.

In addition to the exciting scientific program, we hope you enjoy our social program in one of the most attractive Middle East countries, Egypt.

*Looking forwards to see you in 15th AASD conference
In Shaa Allah. 23 – 26 October 2019*

**AASD & Conference President
Prof Inass Shaltout**



AASD Annual Conferences:

1 st	AASD Annual Conference, Cairo	20-21 December 2006.
2 nd	AASD Annual Conference, Cairo	28-30 November 2007.
3 rd	AASD Annual Conference, Cairo,	29-31 October 2008.
4 th	AASD Annual Conference, Cairo	18-20 November 2009.
5 th	AASD Annual Conference, Cairo	08-10 December 2010.
6 th	AASD Annual Conference, Cairo / Red Sea	16-18 June 2011.
7 th	AASD Annual Conference, Cairo / Porto Marina	12-16 September 2012
8 th	AASD Annual Conference, Cairo / Hurghada	17-21 December 2013
9 th	AASD Annual Conference, Cairo / Red Sea	29 October – 2 November 2014
10 th	AASD Annual Conference, Cairo / Red Sea	20-22 October 2015
11 th	AASD Annual Conference, Cairo	11-13 October 2016
12 th	AASD Annual Conference, Cairo	11-12 October 2017
13 th	AASD Annual Conference, Cairo	18 April 2018

AASD International Conferences:

- AASD in collaboration with University of Medical Sciences and Technology, Khartoum, Sudan, 1-4 February 2008.
- AASD in collaboration with Moroccan Society of Diabetes and Nutrition SMEDIAN and FMED, Morocco, 1-4 May 2008.
- AASD in collaboration with Moroccan Society of Diabetes and Nutrition SMEDIAN, Morocco, 3-6 march 2016.

AASD National Conferences:

More than 30 conferences till now

AASD Postgraduate Course:

AASD / EASD postgraduate course 16 – 18 November, 2017

AASD Diabetes Co-morbidities and Fasting Conferences:

- 1st Annual Conference, June 2012
- 2nd Annual Conference, June 2013
- 3rd Annual Conference, May 2014
- 4th Annual Conference, May 2015
- 5th Annual Conference, April 2016
- 6th Annual Conference, April 2017

Contact Us:

conferences@aasdonline.com / inassshaltout@hotmail.com
Mobile: 01222341484 - 01226572116 - 01119884994 - 01068223498
facebook.com / aasd.official / .facebook.com aasd.diabetes
www.facebook.com/aasd.official Website: www.aasdonline.com

YouTube: AASD Diabetes, channel has been recently lunched where AASD educational martials and conferences are published

<https://www.youtube.com/channel/UCvpn5xDiJa23VgymBZRXKnQ>

EASD e-Learning

<https://www.easd.org/education/easd-e-learning.html>





International Faculty (alphabetically)



Prof Assaad Aldafter, Bahrain

He is a Consultant Internist & Endocrinologist. He is fellow of Royal College of Physicians, Member of Society of Endocrinology United Kingdom, fellow of Iraq Council of Medical Specialties.



Prof Barkai László, Hungary

László Barkai is full Professor of Pediatrics at University of Miskolc and Pavol Jozef Safarik University in Kosice. He graduated and was awarded Doctorate of Medicine from the University of Debrecen. He was Research Fellow of the Hungarian Academy of Sciences, Budapest and Clinical Research Fellow in Pediatric Endocrinology, Royal Alexandra Hospital for Children, Sydney, NSW. He is serving as Consultant in Pediatrics and in Pediatric Diabetes/endocrinology/metabolism for many years. He has been involved in graduate teaching of Pediatrics and has served as mentor for Pediatric Residents for many years. Several doctors gained specialty certificate in Pediatrics under his mentorship over the past years. Dr. Barkai was awarded PhD and DSc degrees from the Hungarian Academy of Sciences. He gained Habilitation in Medicine at the University of Debrecen. Dr. Barkai's main research interests are epidemiology, pathophysiology and treatment of diabetes mellitus and its complications and cardiometabolic risks in childhood and adolescence. On these areas he has several international cooperations and published many book-chapters and numerous scientific publications in international and national journals. He is supervising research work of several PhD students in the field of childhood diabetes and its complications. Former appointments of Professor Barkai include Dean of Faculty of Health Care, University of Miskolc, Chief Executive Officer for Pediatrics and Neonatology, North-Hungary, Secretary of the Medical and Health Committee, Hungarian Conference of Rectors, Member of the National Health Council, Hungary. Professor Barkai currently is member of international societies, including European Association for the Study of Diabetes, American Diabetes Association, International Society for Pediatric and Adolescent Diabetes and he is an Elected Fellow of Diabetes India. He served as Secretary General and President, currently as Vice President of the Hungarian Diabetes Association. He was awarded many professional and scientific awards for service of child health and research of diabetes and its complications.



Prof Didac Mauricio, Spain

He is Director of the Department of Endocrinology & Nutrition, Hospital de la Santa Creu i Sant Pau, affiliated with the Autonomous University of Barcelona. He is leading the Diabetes Research Group at this institution, that belongs to the excellence diabetes research network CIBER of Diabetes and Associated Metabolic diseases (CIBERDEM), Instituto de Salud Carlos III in Spain. He is currently on leave from his position as Associate Professor at the School of Medicine, University of Lleida. He has published over 190 peer-reviewed articles and has contributed to multiple books. He has received the highest awards from the Spanish Society of Diabetes and the Spanish Society of Endocrinology & Nutrition. He has also served as a member in several local and international committees. D. Mauricio has been principal investigator of several research projects funded by national and international agencies. He keeps a strong interest on current clinical issues in diabetes management, including randomised clinical trials and clinical research on diabetic complications, with special focus on atherosclerotic disease, and also in studies on real-world evidence.



Prof Eleanor Kennedy, UK

She has a BSc in Biochemistry from the University of Glasgow and a PhD in molecular neuropharmacology from the University of Leicester.

Following three years as a postdoctoral student at the University of California, San Diego, Dr. Kennedy became a group leader at the University of Geneva in Switzerland studying the intracellular signalling pathways that stimulate insulin secretion. She also has an MBA from Cranfield School of Management.



Prof. Evgenia Patrakeeva, Russia

She is a teaching assistant in Teaching Assistant in Endocrinology and Consultant Endocrinologist, First Saint-Petersburg Medical University named after I.P. Pavlov. Received her medical degree from First Saint-Petersburg Medical University named after I.P. Pavlov in 2005, where she graduated cum laude and completed her residency in endocrinology and internal medicine at faculty therapy department of this University. Research interests include insulin therapy, patient education, psychological issues in diabetes care, the use of new technologies in diabetes. She also has an interest in development of web-based resources and social media use as components of diabetes therapy and patients' psychological support. Co-founder of educational web-resource (www.rule15s.com) and educational social networks account for Russian-speaking diabetes patients (@diabet.connect). Results of her research were presented at international and local Russian conferences. She has organized on a regular basis the course of continuous postgraduate education for young diabetologists in Saint Petersburg with the aim of recent international research findings translation into everyday clinical practice. Innovative educational course for CSII and ready-for-CSII young patients was also organized with Dr. Patrakeeva's support and personal participation. Member of Russian Endocrinology Society, European Association for Study in Diabetes (EASD), EASD-Postgraduate Education Committee and American Diabetes Association (ADA).



Prof Hamdoun Lhassani, Morocco

He is a specialist in Endocrine & Diabetes, is a graduate of the University of Lille and Amiens, France. Previously worked at university hospitals in northern France Vice-President of the Moroccan Association for endocrine diseases, nutrition and diabetes, Former head of the Moroccan Association for endocrine diseases, nutrition and diabetes Participant in several medical studies, A member of the Francophone Association for Diabetes, A member of the European Association for the study of diabetes, President of the Association of the city of Salé in Morocco to help diabetics, Treasurer of the National Federation of Moroccan diabetics.



Prof Kebira Benabed

She is a Former professor of internal Medicine at the University of Rabat Specialist in Endocrinology, Diabetology and Nutrition, Former Secretary General of the Moroccan Society of Endocrinology, Diabetology and Nutrition (SMEDIAN). Member of the office of the Moroccan League for the Fight against Diabetes President of the organising committee of scientific and social events realized by the Moroccan League for the Fight against Diabetes.



Prof Leszek Czupryniak, Poland

He is a physician researcher, involved mostly in clinical studies on pathogenesis and treatment of type 2 diabetes mellitus, hypertension, and obesity, with particular interest in mechanisms responsible for their co-existence. Since 2015 he has been working as a head of the Department of Diabetology and Internal Medicine at the Warsaw Medical University, in Warsaw, Poland. His medical and research training included scholarship or courses at the United Kingdom Prospective Diabetes Study centre (Oxford Centre for Diabetes, Endocrinology and Metabolism) in Oxford (UK), Maastricht (the Netherlands), King's College, London (UK), Wakefield (UK), Miami (USA). He served as the president of Diabetes Poland (professional scientific Polish diabetes association, 2011-2015), is a member of the Executive Committee of the European Association for the Study of Diabetes (EASD), since 2013 serving the post of Chair of the EASD Postgraduate Education Committee. The latter activity led him to lecture and run workshops at the EASD Postgraduate Courses across many countries since 2009. In 2000-08 he was an active member of the EASD Hypertension in Diabetes Study Group, in 2007 was elected to the Executive Committee of the Group. Since 2004 he has been organizing biannually EASD Minkowski Postgraduate Course in Clinical Diabetes in Wroclaw (Breslau) in Poland. He is an author or co-author of over 150 original papers published in many papers with total Impact Factor over 150. His letters were published in New England Journal of Medicine, Diabetologia, American Journal of Medicine and The Lancet.



Prof Maryam Alsaeed, UAE

She is Senior Specialist in Internal Medicine, Diabetes & Endocrinology

Dr. Al Saeed qualified in medicine from the Royal College of Surgeons in Ireland, Dublin in 2007. She completed her basic specialist training in internal medicine in Beaumont Hospital, Dublin and the University Hospital, Galway in 2012 and was awarded the Membership of the Royal Colleges of Physicians of the United Kingdom. She continued her training as a registrar in Endocrinology and Diabetes at the Mater Misericordiae University Hospital in Dublin before joining the Endocrinology Department at Dubai Hospital, UAE in 2015 where she has been actively involved in the adult endocrine and diabetes outpatient and inpatient service. Dr. Al Saeed also holds a Masters in Medical Science degree in Health Informatics from the National University of Ireland, Galway with a thesis on dietary and medical management of morbid obesity. She is as well certified by the American Association of Clinical Endocrinologists in endocrine neck sonography and fine needle aspiration biopsy of thyroid nodules. She has a special interest in the management of obesity, diabetes, and thyroid disorders.



Prof Massimo Massi-Benedetti, Italy

He is member of national and international professional and non professional diabetes associations, ex Chair of IDF Europe, Ex IDF Vice-president, Chairman of the IDF Science TF. Founder of the Members of the European Parliament Diabetes Working Group, Former member of the Faculty of Medicine and Chair of the Schools of Podology and of Nursing Sciences of the University of Perugia (I); Chair of the Umbria Regional Diabetes Reference Centre; Co-director of the WHO Collaborating Centre for Diabetes Care Improvement. Director of Research and Education at Dasman Institute for Diabetes Research. At present, President of the HUB for International health ReSearch-HIRS. Main areas of diabetes research: pathophysiology; new drugs; advanced systems for insulin delivery; complications; pregnancy; metabolic monitoring; epidemiology, diabetes registries; ethics. Member of EU projects EURODIABETA; DIABCARD 1-4; DIABCARE 1-3; MFIT; DIABSTYLE 1-2; ADICOL, IMMIDIAB, PARENT, CHRODIS, BRIDGE Health and Project leader of B.I.R.O. and EUBIROD.



Prof Mick Kumwend, UK

MSc FRCP (London) FRCP (Edinburgh)

He is Consultant Nephrologist and Clinical Director in Renal and Diabetes Centre Glan Clwyd Hospital - Rhyl Denbighshire United Kingdom

Prof Mick's Research interests include diabetic kidney disease: progression of CKD, cognitive dysfunction, the role of the kidney in glucose metabolism and Management of end stage kidney disease in people with diabetes.



Prof Mohamed ben bendedetti, Morocco

He is former President of the SMEDIAN, Founder and ex-president of the Inter Regional Association of Endocrinology and Founder and member of the Moroccan Group of Thyroid Study.



Prof Rayaz A. Malik, UK

He graduated in Medicine from the University of Aberdeen in 1991, obtained his MRCP in 1996, PhD from the University of Manchester in 1997 and was elected to become a fellow of the Royal College of Physicians in 2007. He was appointed as Consultant Physician and Senior Lecturer in 2001 and as Professor of Medicine and Consultant Physician in 2008 in Central Manchester University Teaching Hospitals and the University of Manchester. He was appointed as Professor of Medicine at Weill Cornell Medicine in 2014 and is an honorary Professor of Medicine and Consultant Physician at Central Manchester University Teaching Hospitals and University of Manchester and visiting Professor of Medicine at Manchester Metropolitan University. He was appointed as the Organizational Official for Weill Cornell Medicine in Qatar in November 2016. Over the last 15 years he has pioneered the use of corneal confocal microscopy, a non-invasive ophthalmic instrument, to quantify diabetic and other peripheral neuropathies. More recently he has applied CCM to establish it as a surrogate for neuronal damage in patients with Stroke, Multiple Sclerosis, Parkinson's disease and Dementia. He was the President of Neurodiab (the diabetic neuropathy study group of the EASD) from 2009-2012. He is an associate editor for Diabetic Medicine (2006 to present); J of Diabetes and its Complications (2012-present), PLOS One (2016- present), BMC Neurology (2009-present) and Advances in Therapy (2009- present). He is on the Juvenile Diabetes Research Foundation Complications and Clinical Investigation Research Committee (2005-present).



Prof Saud Al Sifri, KSA

He has Endocrinology & Metabolism Training Certificate, Western Ontario University, London, Ontario, CANADA, 2003. Honorary Professor of Medicine, Taif University, Consultant Endocrinologist & Diabetes, Director of Postgraduate Residency Training Program, Director of Diabetes & Endocrine Specialist Center, PMH, Chairman of Endocrinology & Diabetes Department in Al Hada & Taif Armed Forces Hospitals, TAIF. The Saudi Board of Internal Medicine.



Prof Tatjana Milenkovic, Macedonia

She is a professor of internal medicine at the University "St Cyril and Methodius", Medical Faculty in Skopje. She works at the Clinic of Endocrinology, Diabetes and Metabolic Diseases since 1985, where in 1995 she has established the Department of education of people with diabetes - and she has been Head of the department ever since. She obtained specialty in Internal Medicine 1991, PhD in Medical Science 1999, and subspecialty in Endocrinology 2004. She was on education and training in UK (Ipswich Diabetes Center), Denmark (Steno Diabetes Center) and Italy. Prof. Milenkovic has published and authored more than 100 scientific articles, and has been principal investigator and co-investigator in 16 scientific projects of which 11 international, including GCP training. She is author of 2 monographs and 5 book chapters. She is a member of the EASD, ADA, IDF, AACE, DESG (member of the Executive Committee). She is the President of Macedonian Diabetes Association, since 2013 and the President of the Macedonian Scientific Association of endocrinologists and diabetologists since 2014.



Advisory Board: (Alphabetically)

Prof Aly El Abbasy
Prof Assem Zeyada
Prof Ebtesam Zakaria
Prof Fahmy Amara
Prof Mabaheg Souka
Prof Moghazy Mahgoub
Prof Mohamed Fahmy Abdel Aziz
Prof Rawia Khater
Prof Sherif Hafez
Prof Soliman Nasr



National Faculty (Alphabetically)

Prof Abdel Khalek Hamed
Prof Abdel Moniem Zaid
Prof Abir Zakria
Prof Ahmed Abdel Salam
Prof Ahmed Saad El Din
Prof Ahmed Taha
Prof Ali Abbassy
Prof Alyaa El Sherbiny
Prof Amal Fouad
Prof Amera Ahmed
Prof Amr Abdel Wahab
Prof Amr El Meligy
Prof Ashraf Attia
Prof Ashraf Reda
Prof Assem Zeyada
Prof Atef Bassyouni
Prof Atef Elbahry
Prof Ayman El Menofy
Prof Ebtesam Zakaria
Prof El Sayed Farag
Prof Elham Islam
Prof Eman El Shorbagy
Prof Emmy Nasr
Prof Enayat Ezzat
Prof Fahmy Amara
Prof Farid Fawzy
Prof Gamal Ali Badr
Prof Gelsen Saleh
Prof Hala Kahla
Prof Hala Mohamed Ali
Prof Hala Naguib Hosny
Prof Hanan Taha
Prof Hanan Gawish
Prof Hani Hammad
Prof Hazem Ashmawy
Prof Hazem Khamis
Prof Hesham Abu Esha
Prof Hesham El Borolosy
Prof Hesham El Hefnawy
Prof Hesham Habib
Prof Hisham Magd El Din
Prof Hoda Goda
Prof Hosny El Fayoumi
Prof Hosny Salama
Prof Hussein Shalby
Prof Hussein El Fishawy
Prof Ibrahim Awadin
Prof Ihab Salem

Prof Iman El Sherif
Prof Iman Kamel
Prof Inass Shaltout
Prof Khaled El Hadidy
Prof Khaled Hadhoud
Prof Laila Mahmoud
Prof Lobna El Touny
Prof Mabaheg Souka
Prof Magdy Helmy
Prof Maggi Said El Nahdy
Prof Maha Mowafy
Prof Maha Rakha
Prof Manal Helal
Prof Mayada Mohamed Mousa
Prof Mazen Attia
Prof Meghad Abu El Magd
Prof Moghazi Mahgoub
Prof Mohamed Assy
Prof Mohamed Awad
Prof Mohamed El Bahrawy
Prof Mohamed Fahmy Abdel Aziz
Prof Mohamed Hassanein
Prof Mohamed Kamar
Prof Mohamed Naguib
Prof Mohamed Nasr
Prof Mohamed Sharaf Eldin
Prof Mona Mansour
Prof Nabil Farag
Prof Nader Wadie
Prof Nagwa Samy
Prof Nehal Hamdy
Prof Nasrat Ayad
Prof Nermeen Rashed
Prof Omar El Saadany
Prof Raafat Rashwan
Prof Raief Malak
Prof Rasha Azmy
Prof Rasha Sobh
Prof Rawia Khater
Prof Samir Naim Assaad
Prof Sayed Gad
Prof Sherif Hafez
Prof Soliman Nasr
Prof Tarek Fayad
Prof Thana Gzarein
Prof Yasser Abdel Hamid
Prof Yehia Ghaniem
Prof Yasser Al Khwas

AASD Organizing Office:

Mr. Gamal Badry Mr. Raafat Attia Mr. Ahmed Saeed Mr Ahmed Bakry
Mr. Morad Mohsen Mr. Ahmed Ibraheim Mr. Omar Gad



Tuesday 23 October, 2018

Hall B Laylaty
Workshop, IDF Center of Education

08:30– 09:30 Registration

09:30 – 10:00 Workshop (1) Diabetes and cardiovascular comorbidities

Speaker: Prof Maha Rakha

Moderator: Prof Emmy Nasr

10:05 – 10:35 Workshop (2) Diabetic nephropathy.....What nephrologists know more ?

Speaker: Prof Hani Hammad

Moderator: Prof Nader Wadie

**10:40 – 11:10 Workshop (3) Patient Reported Outcome Measure (PROMS) as the
prerequisite for Value Based Diabetes Care**

Speaker: Prof Massimo Massi Benedetti (Italy)

Moderator: Prof Omar El Saadany

11:15– 11:45 Workshop (4) Diabetes research – How to do it? How to fund it?

Speaker: Prof Eleanor Kennedy, UK

Moderator: Prof Inass Shaltout

**11:50 – 12:40 Workshop (5) Strategies for the prevention of diabetes related
complications**

Speaker: Prof Mick Kumwenda, UK

Moderator: Prof Ahmed Saad El Din

12:45 – 01:25 Workshop (6) Diabetic foot ulcers

Speaker: Prof Rayaz A. Malik, UK

Moderator: Prof Inass Shaltout

01:25 – 01:45 Coffee Break



Tuesday 23 October, 2018

Hall B Laylaty
Workshop, IDF Center of Education

01:45 – 02:25 Workshop (7) Diabetes and Geriatric Times

Speaker: Prof Inass Shaltout

Moderator: Prof Ashraf Attia

02:30 – 03:10 Workshop (8) Vitamin D & PTH: clinical case presentation

Speaker: Prof Assem Zeyada

Moderator: Prof Omar El Saadani

03:15 – 03:55 Workshop (9) Diabetic neuropathy, meet the expert

Speaker: Prof Rafaat Rashwan

Moderator: Prof Abdel Khalek Hamed

04:00 – 04:40 Workshop (10) Diabetes and liver or NAFLD, present status

Speaker: Prof Abdel Khalek Hamed

Moderator: Prof Mohamed Naguib

04:45 – 05:25 Workshop (11) Management hyperglycemic emergencies

Speaker: Prof Abir Zakrian

Moderator: Prof Yasser Abdel Hamid

05:30 – 06:00 Workshop (12) DPP4 inhibitors drugs

Speaker: Prof Hesham Habib

Moderator: Prof Abir Zakaria

06:00 Lunch



Wednesday 24 October, 2018

08:00 – 08:45	Registration
09:00– 10:25	Session 1 Opening session Kasr Al Ainy Faculty of Medicine, Cairo University

Chairpersons: (Alphabetically)

Prof Ebtesam Zakaria
Prof Hala Naguib Hosny
Prof Mohamed Naguib
Prof Mona Mansour
Prof Nehal Hamdy
Prof Rawia Khater
Prof Soliman Nasr

Speakers:

Pleotropic actions of antihypertensive drugs	17 Min
Prof Yasser Abdel Hamid	
Diabetes & Pregnancy	17 Min
Prof Hala Kahla	
Diabetes resission: is It Real or Fake	17 Min
Prof Amr El Meligy	
Challenges in diabetes guidelines	17 Min
Prof Inass Shaltout	
Discussion	10 Min



Wednesday 24 October, 2018

**Opening Ceremony
10:30 – 11:05**

- | | |
|--|---------------|
| ❖ Prof Raafat Rashwan
AASD & Conference Honorary President | 3 Min |
| ❖ Prof Hussien Khairy
President of Egyptian Medical Syndicate | 5 Min |
| ❖ Prof Inass Shaltout
AASD & Conference President | 2 Min |
| ❖ Prof Omar El Saadany
Conference Vice President | 2 Min |
| ❖ Prof Abdel Khalek Hamed
Conference & AASD Secretary | 2 Min |
| ❖ Prof Amr Abdel Wahab
Scientific Committee Chairman | 2 Min |
|
<u>Welcome Speech</u> | |
| Prof Nam Han Cho
President of International Diabetes Federation, IDF | 4 Min |
| ❖ Honoring the pioneers & Media Experts | 10 Min |
|
AASD in 14 Years | |
| Prof Inass Shaltout | 5 Min |



Wednesday 24 October, 2018

Session 2
11:10– 12:00

Chairpersons: (Alphabetically)

Prof Ahmed Taha
Prof Amr Abdel Wahab
Prof Hamdoun Lhassani (Morocco)
Prof Mohamed Fahmy Abdel Aziz
Prof Rawia Khater
Prof Sherif Hafez

Speakers:

Perspectives for the application of Artificial Intelligence in Diabetes Care"

Prof Massimo Massi Benedetti, Italy **20 Min**

Diabetic peripheral neuropathy

Prof Rayaz A. Malik, UK **20 Min**

Discussion **10 Min**

12:00– 12:20 Coffee Break

Session 3
12:30– 01:20

Chairpersons: (Alphabetically)

Prof Assaad Aldaftter (Iraq)
Prof Hala Kahla
Prof Inass Shaltout
Prof Massimo Massi Benedetti (Italy)
Prof Mick Kumwenda (UK)
Prof Raief Malak

Speakers:

Best Diet for Diabetes

Prof Tatjana Milenkovic (Macedonia) **20 Min**

Getting involved in diabetes research

Prof Eleanor Kennedy (UK) **20 Min**

Discussion **10 Min**



Wednesday 24 October, 2018

Session 4

Chairpersons: (Alphabetically)

- Prof Kebira benabed (Morocco)
Prof Moghazi Mahgoub
Prof Mohamed ben bendedetti (Morocco)
Prof Mohamed Fahmy Abdel Aziz
Prof Raief Malak

Speakers:

- DPP4 inhibitors
Prof Rayaz A. Malik, UK

Novartis Symposium
01:30– 02:10



Speakers:

- Residual cardiovascular risk of Vildagliptin
Prof Yehia Ghaniem 30 Min

Session 5
02:15 – 03:35

Chairpersons: (Alphabetically)

- Prof Atef Elbahry
Prof Hamdoun Lhassani (Morocco)
Prof Mick Kumwenda (UK)
Prof Moghazi Mahgoub

Speakers:

- Current trends in pediatric diabetes
Prof Barkai László (Hungary) 20 Min
- Hypoglycemia risks and management
Prof Tatjana Milenkovic (Macedonia) 20 Min
- Issues in the transition from pediatric to adult diabetes care
Prof Barkai László (Hungary) 20 Min
- Diabetes mellitus type 1.5 Myth or truth
Prof Assaad Aldaftar (Iraq) 20 Min



 NOVARTIS

Novartis Pharma S.A.E
3 El Sawah St., El Amiria, Cairo, Egypt
P.O. Box 1893 - Code 11511
Tel.: +20 2 22861000
Fax: +20 2 24505345
www.novartis.com.eg

(23)

661485/2



Wednesday 24 October, 2018

Session 6
Sanofi (1) Symposium
03:40 – 04:10

Chairpersons: (Alphabetically)

Prof Atef Bassyouni
Prof Farid Fawzy
Prof Gamal Ali Badr
Prof Hazem Ashmawy
Prof Ibrahem Awadin
Prof Nader Wadie

Speakers:

Why Glimepiride out of all OADs?
Prof Omar El Saadany

30 Min

Session 7
EVA Pharma Symposium
04:15 – 04:35



Chairpersons: (Alphabetically)

Prof Atef Bassyouni
Prof Gamal Ali Badr
Prof Hisham Magd El Din
Prof Nader Wadie
Dr Sayed Gad

Speakers:

Diabetic Neuropathy;.... Evidence based medicine?!
Prof Yehia Ghaniem

20 Min

**FEEL
THE
TOUCH**

R-Alpha Lipoic Acid + Benfotiamine + Cyanocobalamin
THIOTACID COMPOUND
The ideal pathogenetic treatment for diabetic neuropathy

The Ideal
PATHOGENETIC TREATMENT
For Diabetic Neuropathy

- Counteracts micro and macroangiopathy.
- Promotes regeneration of damaged nerve fibers.
- Blocks all hyperglycemic destructive pathways.
- Improves Total Symptom Score of peripheral neuropathies.



Vildagliptin 50 mg + Metformin hydrochloride 850 / 1000 mg

GLIPTUS PLUS
For a safe and effective glycemic control

The Master Glycemic Control





Wednesday 24 October, 2018

Session 8
04:40– 05:45

Chairpersons: (Alphabetically)

Prof Atef Elbahry
Prof Hala Mohamed Ali
Prof Hisham Magd El Din
Prof Ibrahim Awadin
Prof Mabaheg Souka
Prof Raafat Rashwan

Speakers:

Challenges in finding the cure for type 1 diabetes

Prof Mick Kumwend (UK) **20 Min**

Treat the whole not only the hole

Prof Farid Fawzy **20 Min**

Diabetes damage and repair

Prof Abir Zakaria **20 Min**

Discussion **5 Min**

05:45 Lunch

YouTube: AASD Diabetes, channel has been recently lunched where AASD educational martials and conferences are published

<https://www.youtube.com/channel/UCvpn5xDiJa23VgymBZRXKnQ>

EASD e-Learning

<https://www.easd.org/education/easd-e-learning.html>



Thursday 25 October, 2018

Session 10
10:05 – 11:20

Chairpersons: (Alphabetically)

Prof Hussein El Fishawy
Prof Inass Shaltout
Prof Omar El Saadany
Prof Tarek Fayad
Prof Yasser Abdel Hamid

Speakers:

Internet, media, social networks

Prof Evgenya Patrakeeva (Russia) **20 Min**

Preventing micro complications

Prof Leszek Czupryniak (Poland) **20 Min**

EASD/ADA Consensus report on management of hyperglycemia in type 2 diabetes: keypoints"

Prof Didac Mauricio (Spain) **30 Min**

Discussion **5 Min**

Session 11
Sanofi (2) Symposium
11:20 – 12:10



Chairpersons: (Alphabetically)

Prof Ayman El Menofy
Prof Hanan Gawish
Prof Hesham El Borolousy
Prof Mabaheg Souka
Prof Mohamed Awad
Prof Raafat Rashwan

Speakers:

Bright Study (The 1st Head-to-head study comparing insulin glargine U300 to insulin degludec)

Prof Inass Shaltout **30 Min**

Discussion **20 Min**



Amaryl[®]

glimepiride

29

SANOFI

For Healthcare Professionals Only
SAEG.GU.17.11.0224

ROSITOR

Rosuvastatin 10mg&20mg Film Coated Tablets

A Super-Statin[^]

for prevention of cardiovascular events *
(for patients at high risk)




SANOFI

30

For Healthcare Professionals Only

[^]Nardi G., et al. Potential Phototoxicity of Rosuvastatin Mediated by Its Dihydrophenanthrene-like Photoproduct. Chem Res Toxicol. 2011 Oct 17;24(10):1779-85.
* ROSITOR approved prescribing information 4/7/2015.



Toujeo®
insulin glargine 300U/mL



SAEG.IJO.17.12.0274



SANOFI

For further information please contact : SANOFI Egypt
3, EL Massanah St., Zeitoun, Cairo , Egypt , P.O. BOX : 1486
Tel.: +202 22860000-22860060 Fax: + 202 22860107- 22860112
www.sanofi.com



Thursday 25 October, 2018

Session 12
AstraZeneca Symposium
12:10 – 12:40



Chairpersons: (Alphabetically)

Prof Fahmy Amara
Prof Laila Mahmoud
Prof Meghad Abu El Magd
Prof Mohamed Assy
Prof Nasrat Ayad
Prof Tarek Fayad

Speakers:

SGLT-2i: A paradigm shift in T2D Management Prof Hesham El Hefnawy	15 Min
SGLT2-inhibitors: moving from neutrality to benefits Prof Inass Shaltout	15 Min

12:40 – 01:00 Coffee Break and poster session discussion in the poster area

Posters

- ❖ Discover Trial
- ❖ The relationship between serum osteoprotegerin level and coronary artery calcification in type 2 diabetes mellitus patients

Presented by: Prof Rasha Sobh

YouTube: AASD Diabetes, channel has been recently lunched where AASD educational martials and conferences are published

<https://www.youtube.com/channel/UCvxn5xDiJa23VgymBZRXKnQ>

EASD e-Learning

<https://www.easd.org/education/easd-e-learning.html>

For Health Care Professionals only



FRX-300-255-ROL-1017-1019

00240006/010001018D

**EXCESS
GLUCOSE OUT.
RESULTS IN.**



FORXIGA is a sodium-glucose co transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Dose The recommended starting dose is 10 mg once daily, taken in the morning, with or without food. Assess renal function before initiating FORXIGA. Do not initiate FORXIGA if eGFR is below 60 mL/min/1.73 m². Discontinue FORXIGA if eGFR falls persistently below 60 mL /min/1.73 m². CONTRAINDICATIONS History of serious hypersensitivity reaction to FORXIGA. Severe renal impairment, end-stage renal disease, or dialysis. WARNINGS AND PRECAUTIONS: Hypotension: Before initiating FORXIGA, assess volume status and correct hypovolemia in the elderly, in patients with renal impairment or low systolic blood pressure, and in patients on diuretics. Monitor for signs and symptoms during therapy. Impairment in renal function: Monitor renal function during therapy. ADVERSE REACTIONS : The most common adverse reactions associated with FORXIGA low blood sugar level when taking with sulphonyl urea. Common were genital infections, itching, back pain, passing more water than usual, changes in amount of cholesterol or fats in blood, changes in amount of red blood cells, dizziness. SE IN SPECIFIC POPULATIONS : Pregnancy: There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers: Discontinue FORXIGA or discontinue nursing. Geriatrics: Higher incidence of adverse reactions related to reduced intravascular volume. Renal Impairment: Higher incidence of adverse reactions related to reduced intravascular volume and renal function. There are other uncommon side effect. Please read full prescribing information. Healthcare professionals asked to report any adverse event.

- 1- Always read the full prescribing information. (if not already present in the promotional material)
- 2- Other less common side effects are listed in full prescribing information. (if not already present in the promotional material)
- 3- Healthcare professionals are asked to report any suspected adverse reactions.



133, 90 North Street, 5th district, New Cairo T: +002/02 2703 2445 F: +002/02 2703 6880 www.astrazeneca.com
In order to monitor the safety of AstraZeneca products, we encourage reporting any side effects experienced while taking an AstraZeneca product.
E-mail: Patient.safetyegypt@astrazeneca.com For further medical information, please send to: medinfo-egypt@astrazeneca.com



Thursday 25 October, 2018

Session 13
EAVA@cardiorisk join session
01:00 – 01:55

Chairpersons: (Alphabetically)

Prof El Sayed Farag
Prof Hazem Khamis
Prof Mohamed Assy
Prof Mohamed El Bahrawy
Prof Nehal Hamdy
Prof Rawia Khater

Speakers:

The triglyceride dilemma

Prof Ashraf Reda **15 Min**

What we should know from PCSK9 inhibitors, recent outcomes trials

Prof Atef Elbahry **15 Min**

Diabetic patients &CHD: search for the culprit

Prof Nabil Farag **15 Min**

Discussion **10 min**

Session 14
02:00 – 02:25
Plenary Session

Chairpersons: (Alphabetically)

Prof Ali Abbassy
Prof Fahmy Amara
Prof Hesham Abu Esha
Prof Magdy Maglaa

Speakers:

Metabolic surgery, its benefits and limitations

Prof Leszek Czupryniak (Poland) **20 Min**

Discussion **5 Min**



(sitagliptin/metformin, MSD)

In patients with type 2 diabetes mellitus uncontrolled on diet and exercise alone

**Start early with JANUMET™:
Powerful HbA_{1c} reductions,
as much as 3.6%^{1,a}**

-3.6%
HbA_{1c} reduction
at 18 weeks^a
(N=559)

Reference

¹ Reaven et al. The effect of initial therapy with the fixed dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 13: 644 - 652, 2011.



67, 9th Street, New Cairo

Tel.: +202 261 45100, Fax: +202 261 31820

*Januvia®/Janumet® are registered trademarks of Merck and Co., Inc., Whitehouse Station, NJ, USA.¹

Trademark of MSD Singapore Company, LLC

Copyright © April 2013 MSD LLC

All rights reserved. October 2014.

DIA-B-109-4080-0000

www.merck.com



Thursday 25 October, 2018

Session 15
MSD Symposium
02:30 – 03:00



Chairpersons: (Alphabetically)

Prof Inass Shaltout
Prof Omar El Saadany

Speakers:

Making choices: DPP4 inhibitors, SGLT2 inhibitors, or both – when and why in taking the next steps after metformin

Prof Leszek Czupryniak (Poland) **20 Min**

Discussion **10 Min**

Session 16
Lilly Symposium
03:05 – 03:35



Chairpersons: (Alphabetically)

Prof Ahmed Abdel Salam
Prof Ali Abbassy
Prof Ayman El Menofy
Prof Elham Islam
Prof Fahmy Amara
Prof Thana Gzarein

Speakers:

An overview of concentrated insulin

Prof Omar El Saadany **20 Min**

Discussion **10 min**



Insulin 1

This section displays five insulin products:

- Humalog**: Insulin lispro injection (rDNA origin)
- Humalog^{mix 50}**: 50% insulin lispro (rDNA origin) injection, 50% insulin lispro protamine suspension
- Humalog^{mix 25}**: 25% insulin lispro (rDNA origin) injection, 75% insulin lispro protamine suspension
- Humulin ^N**: RNP human insulin (recombinant DNA origin)
- Humulin ^R**: Regular U-500 (Concentrated) Insulin Human Injection, USP (recombinant DNA origin)
- Humulin ^{70/30}**: 70% human insulin isophane suspension, 30% human insulin injection (rDNA origin)

Three photographs illustrate insulin use: a girl listening to music while holding an insulin pen, a boy holding a soccer ball, and a woman holding a child.

Device 2

This section displays three insulin pens:

- HumaPen® savvio**: A red insulin pen.
- HumaPen® LUXURA™ HD**: A green insulin pen.
- Humalog KwikPen®**: A blue insulin pen.

Three photographs illustrate the use of these devices: a person using a HumaPen savvio, a child holding a soccer ball next to a HumaPen LUXURA HD, and a person using a Humalog KwikPen.

Support 3

DIABETES CONVERSATIONS

Conversation Map™ education tools provide engaging experiences that can make a difference

health interactions International Diabetes Federation

For further information, contact Eli Lilly & Company's Scientific Offices:

A2 "Double wing" BB007 Cairo Festival City 3rd floor,
5th settlement, New Cairo, Egypt
Phone: +202 24965300 Fax: +202 22685636





Thursday 25 October, 2018

Session 17
Servier Symposium
03:40 – 04:00



Chairpersons: (Alphabetically)

Prof Ahmed Abdel Salam
Prof Ebtesam Zakaria
Prof Enayat Ezzat
Prof Hanan Gawish
Prof Thana Gzarein
Prof Laila Mahmoud

Speakers:

Gliclazide MR, The SU with evidence, recommendations & experience
Prof Abir Zakaria **20 Min**

Session 18
Novonordisk Symposium
04:05 – 04:25



Chairpersons: (Alphabetically)

Prof Enayat Ezzat
Prof Hanaa Taha
Prof Hesham Habib
Prof Hosny El Fayoumi
Prof Meghad Abu El Magd
Prof Mohamed Kamar

Speakers:

Tresiba: The Ultra long basal insulin
Prof Magdy Helmy **20 Min**



STRONGEST HBA1C REDUCTION

-4.3% ↓

Once-daily
TRESIBA®
 100U/ml insulin degludec
 solution for subcutaneous
 injection
ULTRA-LONG
 DURATION OF ACTION^{3,4}

GET HbA_{1c} DOWN WITH CONTROL



- **Successful reductions in HbA_{1c}^{1,2}**
- **Lower risk of nocturnal hypoglycaemia vs glargine^{1,2}**
- **Flexibility in day-to-day dosing time when needed³**
 ...delivered in a once-daily dose.



ECA/TB/0616/0270

References: 1. Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skjøth TV, Rana A, Mathieu C on behalf of the BEGIN Once Long Trial Investigators. Comparison of insulin degludec with insulin glargin in insulin-naïve subjects with Type 2 diabetes mellitus. *Diabetologia* 2013;56(11):1298-304. 2. Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR on behalf of the BEGIN Basal-Bolus Type 1 Trial Investigators. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargin in basal-bolus treatment with mealtime insulin apart in Type 1 diabetes (BEGIN Basal-Bolus Type 1): 2-year results of a randomized clinical trial. *Diabetic Medicine* 2013;30(11):1293-297. 3. Tresiba approved insert leaflet by Egyptian Ministry of health on 11.08.2015. 4. Jonasson I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. *Pharmaceutical Research* 2012;29(8):2104-14.



TRESIBA®
 insulin degludec [rDNA origin] injection



Thursday 25 October, 2018

04:30 – 04:35

MUP presentation

5 Min

Our quality is not an act, it is a habit.

Session 19

04:35 – 05:55

Chairpersons: (Alphabetically)

Prof Amera Ahmed

Prof El Sayed Farag

Prof Hoda Goda

Prof Mayada Mohamed Mousa

Prof Nasrat Ayad

Prof Nermene Rashed

Speakers:

Bets cell rescue

Prof Mohamed Kamar

17 Min

Glucose lowering therapy in type 2 diabetes patients with CVD

Prof Mohamed Awad

17 Min

HbA1c pitfalls

Prof Magdy Helmy

17 Min

Prediabetes

Prof Khaled El Hadid

17 Min

Discussion

8 Min

Session 20

Liptis

06:00 – 06:20



Chairpersons: (Alphabetically)

Prof Hesham El Borolousy

Prof Hesham Habib

Prof Ibrahim Awadin

Prof Mohamed Awad

Prof Rasha Azmy

Prof Yasser Al Khwas

Speakers:

Diabetic Dyslipidemia updates

Prof Khaled El Hadid

20 Min

06:30 Lunch

Glybofen®

5/1000

Glyburide/Metformin HCl

Keeps Diabetic Patient Protected





Thursday 25 October, 2018

Hall B Laylaty

Launch of education program for nurses

AASD In collaboration with Nursing Faculty, Cairo University

Specialty Diabetes Nurse – Diabetes Educator

IDF Centre of education

01:30 – 02:30

Introduction

10 min

Gestational Diabetes and it's impact on maternal health

Prof Abeer Saad Eswi 20 min

Dean of Faculty of Nursing, Cairo University

Introduction to diabetes in the world and Egypt

Prof Inass Shaltout 20 min

AASD President

YouTube: AASD Diabetes, channel has been recently lunched where AASD educational martials and conferences are published

<https://www.youtube.com/channel/UCvpn5xDiJa23VgymBZRXKnQ>

EASD e-Learning

<https://www.easd.org/education/easd-e-learning.html>



Friday 26 October, 2018

Session 21
Breakfast session
09:00 – 09:35

Chairpersons: (Alphabetically)

Prof Emmy Nasr
Prof Fahmy Amara
Prof Farid Fawzy
Prof Hani Hammad
Prof Lobna El Touny

Speakers:

Ageing endocrinology

Prof Rasha Sobh **15 Min**

Rheumatoid arthritis and diabetes mellitus is there is a link

Prof Amal Fouad **15 Min**

Discussion **5 Min**

Session 22
Diabetes in Special Situation
09:40 – 10:25

Chairpersons: (Alphabetically)

Prof Amal Fouad
Prof Amr El Meligy
Prof Emmy Nasr
Prof Hussein El Fishawy
Prof Maha Mowaly
Prof Saud Al Sifri, KSA

Speakers:

Diabetes in pregnancy from preconception to postpartum

Prof Lobna El Touny **20 Min**

Diabetes and autoimmune thyroid disease

Prof Ali Abbassy **20 Min**

Discussion **5 Min**



Friday 26 October, 2018

Session 23
Meet the expert session
10:30 – 11:35

Chairpersons: (Alphabetically)

Prof Elham Islam
Prof Hala Kahla
Prof Mabaheg Souka
Prof Mazen Attia
Prof Samir Naim Assaad
Prof Tarek Fayad

Speakers:

Structured education beyond glycemic control

Prof Mick Kumwenda, UK **20 Min**

Diabetes care in digital era

Prof Evgenya Patrakeeva, Russia **20 Min**

Updates on recent trials in type 2 diabetes

Prof Mick Kumwenda, UK **20 Min**

Discussion **5 Min**

11:35 – 12:15 **Friday prayer**

12:15 – 12:30 **Coffee Break**



Friday 26 October, 2018

Session 24
Diabetes Research Updates
12:40 – 01:45

Chairpersons: (Alphabetically)

Prof Iman El Sherif
Prof Maggi Said El Nahdy
Prof Maha Mowafy
Prof Mazen Attia
Prof Mohamed Nasr
Prof Samir Naim Assaad

Speakers:

Discover Trial

Prof Inass Shaltout **15 Min**

Strategy of CABG in diabetic patients on pump versus off pump

Prof Mohamed Nasr **20 Min**

Gut Microbiota and Diabetes treatment

Prof Samir Naim Assaad **20 Min**

Discussion **10 Min**

Launch of education program for doctors
AASD In collaboration with Medical Syndicate
01:50 – 02:00

Prof Mohamed Nasr

Prof Inass Shaltout

Prof Ola Khairallah



hikma.

**The 1st
Alogliptin
in Egypt**

- Powerful HbA1c Reduction.**
- Effective As Mono Therapy Or In Combination With Other Antidiabetics.**
- Durable Efficacy.**
- Placebo like cardiovascular safety profile (MACE).**
- Extra cardiovascular benefits.**

Smart Control

12 El-Esraa St, of Lebanon St, Giza - Egypt
T (+2) 02 330 479 53/(-2) 02 334 488 61/4
F (+2) 02 330 507 39
www.hikma.com

47



Friday 26 October, 2018

Session 25
Zagazig University Session
02:05 – 03:05

Chairpersons: (Alphabetically)

- Prof Amera Ahmed
Prof Mayada Mohamed Mousa
Prof Nagwa Samy
Prof Nermene Rashed

Speakers:

Diabetes and Brain

Prof Khaled Hadhoud **17 Min**

Management of DM in hospital

Prof Ihab Salem **17 Min**

Management of Type 2 DM in renal impairment

Prof Eman El Shorby **17 Min**

Discussion **9 Min**

Session 26
03:10 – 04:00

Chairpersons: (Alphabetically)

- Prof Ayman El Menofy
Prof Eman El Shorby
Prof Hazem Ashmawy
Prof Iman El Sherif
Prof Khaled Hadhoud
Prof Nagwa Samy

Speakers:

Hikma Presentation

Role of Alogliptin in management of type 2 diabetes **20 Min**

hikma.



Ascensia Diabetes Care Presentation **15 Min**

Newer machine newer technology

AI Asraa Pharmaceutical Presentation **5 Min**

Utopia Presentation

Break pain Triad in PDN **5 Min**





Contour.
diabetes solutions

Accuracy comes first

CONTOUR™ PLUS

Remarkable accuracy in the
hands of patients, as well
as in the laboratory



Second-Chance™ Sampling



The CONTOUR™ PLUS blood glucose monitoring system from Bayer:

Meets the more stringent

ISO* 15197:2013 accuracy requirements

Demonstrated accuracy even at tighter error limits, such as ± 10 mg/dL or $\pm 10\%$.

Percentage of accurate results in the lab according to ISO* 15197:2013 ^a			
Blood glucose concentrations ^b	Within specified error limits of ± 15 mg/dL or $\pm 15\%$	Within specified error limits of ± 10 mg/dL or $\pm 10\%$	Within specified error limits of ± 6 mg/dL or $\pm 6\%$
<100 mg/dL	100%	100%	88%
≥ 100 mg/dL	100%	99%	90%



Second-Chance™ Sampling
Meets the more stringent
ISO 15197:2013 accuracy requirements

HIGHLY ACCURATE

multi pulse™ Accuracy Technology

NO CODING™

0800 800 8001

www.me.diabetes.ascensia.com

رقم خدمة
العملاء
المجتبي

f Contour Egypt



Friday 26 October, 2018

Session 27
04:00 – 05:10

Chairpersons: (Alphabetically)

Prof Ehab Salem
Prof Elham Islam
Prof Gelsen Saleh
Prof Hazem Ashmawy
Prof Hesham Habib
Prof Mohamed Naguib
Dr Sayed Gad

Speakers:

Diabetes and Nutrition

Prof Iman Kamel **15 Min**

Ketosis prone diabetes

Prof Manal Helal **15 Min**

Proteinuria and anti proteinuric measures.

Prof Maggi Said El Nahdy **15 Min**

Tuberculosis and diabetes, an old story and a present problem

Prof Hussein Shalby **15 Min**

Discussion **10 Min**

05:15 lunch

Closing Ceremony
Tampola & Lunch



Better Understanding for Egyptian treatment patterns in type II diabetes -The DISCOVER Study



Inass.Shaltout¹

Abstract

Background

Diabetes is a fast-growing health problem in Egypt. The IDF report of 2017 reported 8.2 million diabetics in Egypt which exceeded the WHO expectations for number of diabetics in Egypt in 2030, expected to be with a significant impact on morbidity, mortality, and health care resources. Currently, the prevalence of type 2 diabetes (T2D) in Egypt is around 15.6% of all adults aged 20 to 79.

Objective

To describe disease management patterns and disease evolution over 3 years in patients with type 2 diabetes initiating a second-line glucose-lowering therapy.

Methods

In this report, baseline data were collected according to routine clinical practice at the selected 38 sites, using a standardized electronic case report form. We enrolled 583 patients (mean age: 52.9 ± 9.8 years and mean time from DM diagnosis: 49.2 ± 44.3 months).

Findings

The mean HbA1c value at baseline was $8.6 \pm 1.4\%$, indicating poor glycemic control. The most commonly prescribed first-line medications were metformin or sulfonylurea in the form of monotherapy. For second line-therapy, the majority of patients switched to dual therapy with metformin plus sulfonylureas or DPP-4 inhibitors. Fewer patients switched to triple therapy, treatment by four or more medications or insulin treatment (121, 12, and 35, respectively). The most common reasons were lack of efficacy, weight gain, hypoglycemic events, and side effects, as reported in 549, 54, 25, and 21 patients, respectively. The set treatment target of enrolled patients at the initiation of second-line therapy was an HbA1c level of 6.9%. Follow-up data will assess the outcomes of such changes in the Egyptian population.

Conclusions

This study showed poor glycemic control among Egyptian DM type II patients, initiating second-line treatments. In spite of the high HbA1c levels second line therapy is initiated 5.8 Years after T2DM diagnosis. Metformin represents only 40.2% from patient population as first line therapy. Lack of efficacy was the most common reason for changing first-line treatments. Dual therapy in the form of metformin plus Sulfonylureas or DPP-4 inhibitors was the most commonly prescribed second-line treatment. However, there was a clinical inertia for initiation the second line therapy with 5.8 years.



Culturally Based Pre-Ramadan Education increased Benefits and reduced Hazards of Ramadan Fasting for people with Type 2 Diabetes

Shaltout I., Zakaria A., Abdel Wahab A., Hamed I. and ElSaid N
Faculty of Medicine, Cairo University & Arabic Association of the study of Diabetes & Metabolism, AASD

Abstract

Background: Most Muslim people with diabetes insist to fast during Ramadan. In this study we evaluated the influence of culturally based pre-Ramadan education PRE in addition to standard of care during their regular pre-Ramadan visit on the fasting experience of people with type 2 diabetes, whether on oral antidiabetic OAD or insulin treatment. A secondary objective was to evaluate the effect of PRE on diabetes self-management behaviors during Ramadan as reported by the participants themselves.

Study Design: In 2016, a pre-Ramadan education PRE programme was offered over 2 months preceding Ramadan in the AASD Education centre for different groups of patients with type 2 DM in addition to standard of care during their regular pre-Ramadan visit. One month after Ramadan, we retrospectively analyzed the fasting experience of 1008 type 2 DM patients known to have a stable treatment regimen at least 3 months before Ramadan [47% were PRE participants (PREP) and 53% received standard of care only (Non-PREP)]. Pregnant women, type1 diabetes, and very high risk type 2 patients were excluded.

Results: 1008 type 2 DM patients fasted most of the days of Ramadan. A positive correlation was detected between PRE and the number of days they practiced Taraweeh prayers in the total number of patients, with reduction of HbA1c by 14% and 10% in those who practiced prayers for 20 and 30 days respectively. In a subgroup HbA1c percent reduction showed positive correlation with the number of fasting days, 90.5% of whom were PREP. PRE improved perception of hypoglycemia evidenced by 23% of PREP compared to 7.5% of Non-PREP, ($p= 0.041$). By regression analysis, perception of hypoglycemia showed +ve correlation with the number of fasting days ($p=0.04$), PRE ($p=0.002$), dose adjustment of antidiabetic medications ($p=0.008$), and SMBG ($p=0.013$). Weight changes or breaking the fast due to hypoglycemia showed no significant correlation with the number of fasting days, SMBG, clinic visits during Ramadan, or specific class of anti-diabetic medications, being assumed to be multi-factorial and influenced by non-objective individual, social and cultural factors. However we found a significant difference between PREP and Non-PREP as regards weight reduction; ($p= 0.042$; [figure4]). Among those committed to Taraweeh prayers daily for 30 days, the majority showed either weight reduction (54%) or weight maintenance (38%), opposed to a minority of weight gain (8%) [figure5]. Moreover participants whether PREP or non-PREP reported decrease of appetite, portion size, and repeated reduction of total insulin dose (10-15% total daily dose reduction in the initial 2 weeks; and 25-30% in the last 2 weeks). SMBG was independent on other measurable parameters.

Conclusions: fasting improved the glycemic control of people with type 2 DM in correlation to the number of fasting days. PRE improved perception and response to hypoglycemia by dose adjustment of OAD or insulin. Integrating PRE might have an impact on patients' hedonic food intake, better problem solving behavior with healthier food choice, reduction of appetite and weight, with associated decline of insulin doses, and objective long-lasting improvement of HbA1c. Insulin treatment showed more self-reported hypoglycemic events in fasting compared to regular days, with repeated mandatory reduction of the total insulin dose, which might suggest a cumulative effect of fasting



THE RELATIONSHIP BETWEEN SERUM OSTEOPROTEGRIN LEVEL AND CORONARY ARTERY CALCIFICATION IN TYPE 2 DIABETES MELLITUS PATIENTS

Rasha Sobh Mohamed*, Nehal Hamdy El Said*, Nashwa Said Ghanem*, Mohamed Aly Salem**, and Nagwa Abd El Ghaffar Mohamed***

Department of Internal Medicine*, Department of radiology**, Faculty of Medicine, Cairo University and Department of clinical and chemical pathology, National Research Center***, Cairo, Egypt

Abstract

Background: Osteoprotegerin (OPG) is a member of the tumour necrosis factor receptor superfamily was described as a strong anti-resorptive factor, but lately has been considered as a possible link between bone and vascular disease. Recent studies have evidenced its close relation with the development of diabetes mellitus (DM).

As cardiovascular morbidity is high in diabetic patients, it is evidently crucial to establish noninvasive methods for monitoring vascular changes such as biochemical markers of increased risk for cardiovascular disease (CVD) events such as OPG.

The aim of this study: To determine the relationship between coronary artery calcification (CAC) measured by the Multidetector computed tomography (MDCT) and OPG levels in Type 2 diabetic patients in comparison to healthy controls.

Methods: Our study included 45 type 2 diabetic patients (mean age 51.7 years; 51.1% male) without evidence of previous CVD and 45 healthy control subjects age and sex matched. All subjects were submitted to full history, full examination and lab investigations. Serum OPG concentration measured by an enzyme-linked immunosorbent assay (ELISA) and CAC imaging performed using non contrast CT of the heart.

Results: Significant CAC (>10 Agatston units) was seen in 23 patients (51.11 %).

OPG was significantly high in diabetic patients in comparison to controls with mean 12.9 ± 5.7 mmol/l in cases, and 8.6 ± 0.5 mmol/l in controls (P value < 0.001).

The coronary artery calcification score (CACS) was positively correlated with age and duration of diabetes. The OPG was positively correlated with fasting blood sugar and duration of diabetes. The CACS, OPG showed significant positive correlations with each other after adjustment for age, gender, and other risk factors (odds ratio = 0.043, 95% confidence interval 0.006 to 0.296; p < 0.001). Cut off value of OPG is 10 pg /ml with sensitivity 95.7% and specificity 100%.

Conclusions: These findings suggest that elevated serum OPG involved in coronary artery calcification and could be used in the clinical setting for the early diagnosis of subclinical atherosclerosis, which would allow for strategies to be designed to reduce the cardiovascular event rate in those patients. Thus, further studies are needed to establish whether increased OPG levels in diabetic patients can in fact predict later development of vascular complications.

Keywords: Osteoprotegerin, Coronary artery calcification, Type 2 diabetes mellitus, Multidetector computed tomography.



Shape the future of diabetes



International
Diabetes
Federation



bto BUSAN
TOURISM ORGANIZATION



Lipanthyl® Supra

160 mg film-coated tablet Fenofibrate

IN TG Management

It's A Crime What
TRIGLYCERIDES ARE
Getting away WITH
“”

For Healthcare Professionals Only





 NOVARTIS

Novartis Pharma S.A.E
3 El Sawah St., El Amiria, Cairo, Egypt
P.O. Box 1893 - Code 11511
Tel.: +20 2 22861000
Fax: +20 2 24505345
www.novartis.com.eg

(23)

661485/2



(sitagliptin/metformin, MSD)

In patients with type 2 diabetes mellitus uncontrolled on diet and exercise alone

Start early with JANUMET™:
Powerful HbA_{1c} reductions,
as much as 3.6%^{1,a}

-3.6%
HbA_{1c} reduction
at 18 weeks^a
(N=559)

Reference

¹ Reaven et al. The effect of initial therapy with the fixed dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes, Obesity & Metabolism 13: 644 - 652, 2011.



67, 9th Street, New Cairo

Tel.: +202 261 45100, Fax: +202 261 31820

*Januvia®/Janumet® are registered trademarks of Merck and Co., Inc., Whitehouse Station, NJ, USA.¹

Trademark of MSD Singapore Company, LLC

Copyright © April 2013 MSD LLC

All rights reserved. October 2014.

DIA-B-109-4080-0000

www.merck.com



Lilly | DIABETES

Insulin 1

Humalog
Insulin lispro injection (rDNA origin)
Humalog^{mix 50}
50% insulin lispro (rDNA origin) injection
50% insulin lispro protamine suspension
Humalog^{mix 25}
25% insulin lispro (rDNA origin) injection
75% insulin lispro protamine suspension
Humulin[®] N
RPH human insulin
(recombinant DNA origin)
Humulin[®] R
Regular U-500 (Concentrated)
Insulin Human Injection, USP
(recombinant DNA origin)
Humulin[®] 70/30
70% human insulin isophane suspension
30% human insulin injection
(rDNA origin)

Device 2

HumaPen[®] savvio
HumaPen[®] LUXURA HD
Humalog[®] KwikPen

Support 3

DIABETES CONVERSATIONS
Conversation Map™ education tools provide engaging experiences that can make a difference

health interactions International Diabetes Federation



For further information, contact Eli Lilly & Company's Scientific Offices:

A2 "Double wing" BB007 Cairo Festival City 3rd floor,
5th settlement, New Cairo, Egypt
Phone: +202 24965300 Fax: +202 22685636



Shape the future of diabetes



International
Diabetes
Federation



bto BUSAN
TOURISM ORGANIZATION





**Looking Forwards To See You In
15th AASD Congress 2019
22 – 25 October, 2019
In Shaa Allah**



Contact Us:

conferences@aasdonline.com / inassshaltout@hotmail.com

Mobile: 01222341484 - 01226572116 - 01119884994 - 01068223498

[facebook.com / aasd.official](https://facebook.com/aasd.official) www.facebook.com/aasd.official

Website: www.aasdonline.com



Extreme for Conferences Organization:
01014566699
sheryshawkyextreme@gmail.com
shery.shawky@extreme-egypt.com
www.extreme-egypt.com



Nour Media:
Mobile : 01221622322
01212619997
E-mail: info@nourmedia.org